Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) SEC filings page on Stock Titan brings together the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents provide structured insight into KalVista’s financial condition, governance, capital structure and key events related to its development and commercialization of EKTERLY (sebetralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE).
Investors can review Form 8‑K current reports in which KalVista announces material events, such as FDA approval of EKTERLY, preliminary and quarterly financial results, appointments of new executives and directors, and the issuance of 3.250% Convertible Senior Notes due 2031. These filings describe terms of financing arrangements, board and committee changes, executive employment agreements and stock‑based inducement awards.
Proxy materials such as the DEF 14A definitive proxy statement detail corporate governance matters, including annual meeting agendas, director elections, advisory votes on executive compensation and auditor ratification. They also outline board structure, committee responsibilities and stockholder voting procedures. Periodic reports referenced in the proxy statement, such as the company’s Annual Report on Form 10‑K, provide audited financial statements and broader business discussion.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI‑powered summaries to interpret complex sections, including descriptions of convertible note covenants, events of default, change‑in‑control provisions and compensation arrangements. The filings page is also a key source for tracking any future Forms 3, 4 and 5 that would report insider transactions in KalVista common stock, as well as 10‑Q and 10‑K reports that update on revenue from EKTERLY, research and development spending and liquidity.
By reviewing KalVista’s SEC filings with the help of AI explanations, investors can better understand how the company finances its operations, governs its business and discloses risks and opportunities associated with its rare‑disease portfolio.
KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. These figures are early estimates and rely on the company’s financial closing procedures and the completion of an audit of its financial statements for that transition period. The company emphasized that the final audited results could differ materially from these preliminary numbers. KalVista also released a press release and an updated corporate presentation, which are attached as exhibits to this report.
KalVista Pharmaceuticals (KALV) reported an insider equity transaction by its Chief Development Officer. On 11/20/2025, the officer exercised an employee stock option to acquire 87,390 shares of common stock at an exercise price of $0.0043 per share, coded as transaction type "M" (option exercise). After this transaction, the officer directly beneficially owned 220,964 shares of KalVista common stock. The related employee stock option, which was 100% vested, was fully exercised and no derivative securities remained beneficially owned.
KalVista Pharmaceuticals, Inc. insider activity: the company’s Chief Executive Officer and director reported routine equity award activity. On 11/17/2025, the reporting person acquired 9,364 shares of common stock through the vesting and settlement of restricted stock units (coded “M”), increasing directly held common shares to 408,345. On 11/18/2025, 4,466 shares of common stock were sold at a weighted average price of $14.4794 per share, leaving 403,879 shares of common stock directly owned.
The sale was made to cover tax withholding obligations arising from RSU vesting under a “sell to cover” arrangement and is described as non-discretionary. Related RSU awards provided common shares at no cash exercise price, with portions vesting in equal installments on quarterly anniversaries of their respective vesting commencement dates, subject to continued service.
KalVista Pharmaceuticals, Inc. insider trading report: The company’s Chief Development Officer filed a Form 4 detailing routine equity award activity. On 11/17/2025, the officer acquired 4,205 shares of KalVista common stock following the vesting and settlement of restricted stock units (RSUs), which convert to common stock on a one-for-one basis for no cash consideration. On 11/18/2025, 2,683 shares were sold in a broker-assisted “sell to cover” transaction at a weighted average price of $14.4794 per share to satisfy tax withholding obligations tied to the RSU vesting, described as non-discretionary. After these transactions, the officer beneficially owned 133,574 shares of KalVista common stock, held directly.
KalVista Pharmaceuticals' (KALV) Chief Medical Officer reported equity activity involving restricted stock units and related share sales. On 11/17/2025, 6,447 shares of common stock were acquired through the vesting and settlement of restricted stock units, increasing direct holdings to 128,952 shares. On 11/18/2025, 3,075 shares were sold at a weighted average price of $14.4795 per share to cover tax withholding obligations from the RSU vesting, a non-discretionary "sell to cover" transaction, leaving 125,877 shares directly owned.
The filing also shows RSU awards converting into 2,419 and 4,028 shares of common stock at a conversion price of $0 per RSU. One RSU grant vests in 1/16th increments each quarterly anniversary of its vesting commencement date, and another in 1/12th quarterly increments, in each case conditioned on continued service.
KalVista Pharmaceuticals (KALV) reported insider activity by CEO Benjamin L. Palleiko. On 11/11/2025, 7,120 RSUs vested and were settled into common stock. On 11/12/2025, he sold 3,328 shares at $11.55 to cover tax withholding tied to the RSU settlement. Following these transactions, directly held common stock was 398,981 shares, and derivative securities beneficially owned were 106,800. The RSU award vests in equal quarterly installments beginning November 11, 2025.
KalVista Pharmaceuticals (KALV) reported its first commercial quarter following EKTERLY (sebetralstat) approvals, recording product revenue, net of $13.7 million for the three months ended September 30, 2025. Operating expenses rose with the launch, led by S,G&A of $46.5 million and R&D of $12.0 million, driving an operating loss of $46.1 million and a net loss of $49.5 million (basic and diluted loss per share of $0.92).
Liquidity strengthened: cash and cash equivalents were $243.5 million and marketable securities were $65.7 million. The company issued $143.8 million aggregate principal of convertible notes (balance sheet carrying amount $139.0 million) and reported a royalty obligation with a $125.0 million net carrying amount tied to its DRI agreement. Deferred revenue was $11.5 million from the Kaken upfront. EKTERLY received U.S., UK, EU, Switzerland and Australia approvals in 2025, with commercial sales initiated in the U.S. and Germany.
KalVista Pharmaceuticals (KALV) furnished an update on its latest results. The company reported financial results for the quarter ended September 30, 2025 and provided a related press release as Exhibit 99.1 to this Form 8-K.
The information under Item 2.02, including Exhibit 99.1, is expressly stated as “furnished” and not “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically noted in a future filing.
KalVista Pharmaceuticals insider grant: An officer, Chief Operations Officer Arif Bilal, was granted 100,000 stock options exercisable at $11.49 per share. The option award vests over a four-year schedule with 25% vesting on 10/08/2026 and the remainder vesting monthly thereafter; the options expire on 10/07/2035. Following this transaction the reporting person beneficially owns 100,000 underlying shares on a direct basis. The filing was reported on 10/08/2025.
Arif Bilal, listed as Chief Operations Officer and a director of KalVista Pharmaceuticals, Inc. (KALV), filed an initial Form 3 reporting that no securities are beneficially owned as of the event date 10/06/2025. The filing was signed by an attorney-in-fact on 10/08/2025. This Form 3 records a disclosure obligation under Section 16; instead of listing share ownership or derivative positions, it indicates the reporting person currently holds zero reportable equity or derivative interests.